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and placental abruption: a pilot study
Chunfang Qiu1*, Sixto E. Sanchez2,3, Karin Hevner1, Daniel A. Enquobahrie1,4 and Michelle A. Williams5
Abstract 
Background: Mitochondrial biogenesis and adequate energy production are important for embryogenesis and pla-
centation. Previous studies documented alterations in maternal blood mitochondrial DNA (mtDNA) copy number—a 
marker of mitochondrial dysfunction—in pregnancies complicated by placental abruption. To further understand 
the role of mitochondrial dysfunction in the pathogenesis of placental abruption, we conducted a pilot study using 
placental specimen collected from 103 placental abruption cases and 102 non-abruption controls. Real-time quantita-
tive polymerase chain reaction (PCR) was used to assess the relative copy number of mtDNA in DNA extracted from 
placental samples collected immediately after delivery. Logistic regression procedures were used to estimate adjusted 
odds ratios (OR) and 95 % confidence intervals (CI).
Results: Higher odds of placental abruption was observed with increasing mtDNA copy number (p value for 
trend = 0.05). The odds of placental abruption was elevated among women who delivered placentas with higher 
mtDNA copy number (≥120.5, the median) as compared with those with lower values (<120.5) (adjusted OR = 2.38; 
95 % CI 1.11–5.08).
Conclusion: We found preliminary evidence for associations of target tissue-specific mitochondrial dysfunction with 
an adverse perinatal outcome, placental abruption. Larger studies and replication of findings in other populations 
will further our understanding of relationships between cellular and genomic biomarkers of normal and abnormal 
placental function and vascular placental disorders.
Keywords: Placental abruption, Mitochondrial dysfunction, Placental mitochondrial DNA, Pregnancy, Biomarkers
© 2015 Qiu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Placental abruption, the premature separation of the 
placenta from the uterus, is a life threatening obstetri-
cal condition that complicates approximately 1  % of all 
pregnancies [1–3]. The condition occurs in much higher 
frequencies among women with multi-fetal gestation, 
coagulopathies, acquired forms of thrombophilia, uterine 
anomalies, abdominal trauma, hypertension, premature 
rupture of membranes, maternal-fetal hemorrhage, and 
intrauterine infections [4–8]. Advanced maternal age, 
grand-multiparity, and maternal cigarette smoking have 
been identified as placental abruption risk factors [6–8]. 
Pathophysiologic mechanisms involved in placental 
abruption and related perinatal disorders (e.g., preterm 
birth, preeclampsia, and intrauterine growth restric-
tion) include uteroplacental ischemia, under perfusion, 
chronic hypoxia, and infarctions.
Alterations in mitochondrial DNA (mtDNA) den-
sity (copy number) in various tissues, including whole 
blood, has emerged as a possible biomarker of mitochon-
drial dysfunction, a risk factor for diverse cardiometa-
bolic and neurodegenerative disorders, cancers [9–11], 
and adverse perinatal outcomes [12]. For example, we 
recently reported associations of alterations in mtDNA 
copy number in maternal blood with the risk of placen-
tal abruption [12]. In view of this emerging literature, we 
postulated an association between mtDNA copy number 
in placenta with risk of placental abruption. We used data 
and placental tissues remaining from an earlier study [13] 
to preliminarily test our hypothesis.
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Results and discussion
Socio-demographic, medical, and reproductive char-
acteristics of placental abruption cases and controls 
are summarized in Table  1. Median values of placen-
tal mtDNA copy number were higher among placen-
tal abruption cases as compared with controls (144.3 
vs. 120.5; p-value = 0.14), though the difference did not 
reach statistical significance. After controlling for con-
founding by maternal pre-pregnancy body-mass index, 
employment status during pregnancy, and gestational 
age at delivery we noted a trend of increased risk of pla-
cental abruption with increased mtDNA copy number 
(p for trend test =  0.05). The fully adjusted odds ratios 
(ORs) of placental abruption for the successive quartiles 
of mtDNA copy number, compared with the referent 
(first quartile) were 0.72 [95 % confidence interval (95 % 
CI) 0.22–2.35], 1.91 (95 % CI 0.66–5.52) and 2.15 (95 % 
CI 0.74–6.21) (p for trend = 0.05) (Table 2). Because the 
odds of placental abruption appeared to be increased 
only in the upper two quartiles, we repeated analyses 
after creating a dichotomous variable for high (upper 2 
quartiles) versus low (lower 2 quartiles) mtDNA copy 
number using the median (120.5). From these analyses, 
we noted that the odds of placental abruption were 2.38-
fold higher among women with higher (≥120.5) placental 
mtDNA copy number as compared with those with lower 
(<120.5) values (adjusted OR = 2.38; 95 % CI 1.11–5.08).
Higher placental mtDNA copy number is associated 
with higher risk of placental abruption. The odd of pla-
cental abruption was 2.38-fold higher among women 
Table 1 Maternal characteristics of the placental abruption cases and controls
a Mean ± standard deviation (SD)
b P-value from Student’s t test for continuous variables and Chi square test/Fisher’s Exact test for categorical variables
Characteristics Study groups P-valueb
Placental abruption (N = 103) Comparison group (N = 102)
n % n %
Maternal age at delivery (years)a 27.0 ± 6.6 26.8 ± 5.8 0.89
Maternal age at delivery (years)
 <20 18 17.5 10 9.8 0.29
 20–34 71 68.9 78 76.5
 ≥35 14 13.6 14 13.7
Gravidity
 1 45 43.7 37 36.3 0.21
 2–3 40 38.8 52 51.0
 ≥4 18 17.5 13 12.7
Nulliparous 46 44.7 37 36.3 0.22
Maternal education ≤ high school 76 73.8 69 67.7 0.29
Single marital status 19 18.5 14 13.7 0.29
Employed during pregnancy 58 56.3 44 43.1 0.06
Received prenatal care 94 91.3 97 95.1 0.41
Did not take prenatal vitamins 11 10.7 14 13.7 0.53
Smoked during pregnancy 3 2.9 1 1.0 0.62
Alcohol consumption during pregnancy 9 8.7 0 0.0 0.003
Drug abuse during pregnancy 1 1.0 0 0.0 –
Chronic hypertension 3 2.9 1 1.0 0.42
Preeclampsia 11 10.7 4 3.9 0.11
Pre-pregnancy body mass index (kg/m2)a 23.5 ± 3.2 23.6 ± 3.5 0.84
 Lean (<18.5) 4 3.9 1 1.0 0.57
 Normal (18.5–24.9) 75 72.8 74 72.5
 Overweight (25–29.9) 18 17.5 21 20.6
 Obese (≥30.0) 6 5.8 6 5.9
Gestational age at delivery 34.7 ± 4.3 39.1 ± 1.4 <0.001
Infant birthweight (g) 2388 ± 921 2835 ± 939 <0.001
Stillbirth 21 20.4 0 0.0 <0.001
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who delivered placentas with mtDNA copy number at 
or above the median as compared with those women 
who delivered placentas with mtDNA copy number 
below the median. To the best of our knowledge, this 
is the first report that documents a positive association 
between placental mitochondrial density (copy number) 
and placental abruption. These preliminary data are in 
general agreement with earlier research findings from 
our group [12]. We examined the association of mater-
nal whole blood mtDNA copy number with the odds of 
placental abruption [12] and found that the odds of pla-
cental abruption was positively associated with maternal 
blood mtDNA copy number. Specifically, we found a 1.6-
fold increased odds of placental abruption for mothers 
with blood mtDNA copy number ≥336.9, as compared 
to those with values <336.9. Our present study further 
extends the literature, by documenting a positive associa-
tion of placental abruption risk with evidence of placen-
tal mitochondrial dysfunction as reflected by increased 
mtDNA content/copy number.
The placenta, a highly complex organ which serves as 
the site for nutrient, water, and waste exchange between 
the mother and her fetus, plays an important role in 
modulating placental function and fetal growth. Fur-
ther, as an immune-endocrine organ that constitutes the 
intrauterine environment, the placenta plays an impor-
tant role in mediating the impact of environmental and 
metabolic insults on fetal growth. Mitochondria, cellular 
structures that provide most of the energy production in 
cells, control a number of important cellular processes, 
(e.g., fat metabolism, steroid synthesis, and apoptosis) 
and are likely to play a central role in placental implanta-
tion, growth and development.
Several lines of evidence have provided plausible bio-
chemical mechanisms for the observed association 
of placental mitochondrial dysfunction with placen-
tal abruption. First, mtDNA is known to be highly sus-
ceptible to oxidative damage. This vulnerability has 
been attributed to absence of histones or DNA-binding 
proteins, limited DNA repair mechanisms, intron-less 
mitochondrial genes, rapid replication, and insufficient 
and inaccurate proofreading system [14–16]. Mito-
chondrial DNA damage, particularly deletions in the 
control regions of the circular mitochondrial genome, 
as reflected by alterations in mtDNA copy number, has 
also been shown to alter mitochondrial gene expression 
and lead to a deficiency in oxidative phosphorylation and 
enhanced generation of ATP by glycolysis [17]. Second, 
oxidative stress may contribute to alterations in mito-
chondrial function and increased mtDNA copy numbers 
through mechanisms that involve reactive oxygen species 
(ROS)-induced damage to cellular structural elements 
(including the lipid membranes of mitochondria) [18]. 
ROS may also affect mitochondrial function by damag-
ing DNA and impairing electron chain transport, which 
initiates a compensatory response that increases mtDNA 
copy number [17]. Evidence for this hypothesized mech-
anism is supported by findings from experimental animal 
studies documenting increased mitochondrial damage 
and mtDNA copy numbers with increasing exposure to 
pro-oxidants [18]. Taken together, available epidemio-
logical and other data underscore biologically plausi-
ble mechanisms that may account for the association 
observed in our preliminary study.
Several limitations of the present pilot study merit con-
sideration. First, given the retrospective study design, we 
cannot establish the temporal relationship between ele-
vated placental mtDNA copy numbers and the onset of 
placental abruption. Second, differential misclassification 
of maternal mtDNA copy number is a possibility, though 
unlikely, as all laboratory analyses were conducted with-
out knowledge of participants’ case–control status. Third, 
although we required that all physician diagnosed pla-
cental abruption cases had documented evidence blood 
clot behind the placental margin accompanied by at least 
two of the following clinical signs and symptom (vaginal 
bleeding late pregnant not associate with placenta previa 
or cervical lesions; uterine tenderness and/or abdominal 
Table 2 Odds ratio (OR) and 95 % confidence interval (CI) for placental abruption in relation to categories of placental 
mitochondrial DNA copy number
a Adjusted for maternal pre-pregnancy body mass index, employed during pregnancy and gestational age at delivery
Placental mitochondrial DNA copy number Placental abruption cases (N = 103) Controls (N = 102) Adjusted ORa (95 %CI)
Quartile 1 (<86.5) 22 (21.4) 26 (25.5) 1.00 (reference)
Quartile 2 (86.5–120.4) 17 (16.5) 25 (24.5) 0.72 (0.22–2.35)
Quartile 3 (120.5–191.4) 27 (26.2) 25 (24.5) 1.91 (0.66–5.52)
Quartile 4 (≥191.5) 37 (35.9) 26 (25.5) 2.15 (0.74–6.21)
P-value for linear trend 0.05
 <Median (<120.5) 39 (37.9) 51 (50.0) 1.00 (reference)
 ≥Median (≥120.5) 64 (62.1) 51 (50.0) 2.38 (1.11–5.08)
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pain; and poor fetal tracings suggestive of fetal distress 
or stillbirth), we cannot rule out the possibility that less 
severe placental abruption cases were missed classified 
as non-cases. Fourth, we took biopsy samples from four 
systematically selected sites from each placenta, and we 
pooled the tissues sampled from each participant to then 
estimate mtDNA content for the pooled sample. Hence, 
in this pilot and feasibility study, we are not able to report 
the coefficient of variation for mtDNA content according 
to different biopsies. Future studies are needed to assess 
mtDNA content according to specific cell types. Fifth, 
we used well-established commercially available primers, 
reagents and protocols for mtDNA content determina-
tion, with 2 housekeeping genes (BECN1 and NEB) for 
normalization (NovaQUANT™ Human Mitochondrial 
to Nuclear DNA Ratio Kit); hence we recognize that our 
quantitative real-time PCR experiments may not strictly 
adhere to the MIQE guidelines [19]. Lastly, although we 
controlled for multiple confounding factors, we cannot 
exclude the possibility that the odds ratios reported are 
unaffected by residual confounding.
Conclusions
Our results suggest that mtDNA copy number in placen-
tal tissue, a target tissue, may be associated with placen-
tal abruption. Future research that includes larger study 
populations and replication efforts will be needed to con-
firm our preliminary observations and expand the scope 
of research to include assessment of other measures of 
mitochondrial function and uteroplacental metabolism. 
Finally, analyses that interrogate the influences of varia-
tion in the mitochondrial genome in maternal, fetal and 
uteroplacental compartments are also warranted as 
such studies will elucidate the molecular mechanisms of 
maternal, fetal and uteroplacental bioenergetics during 
pregnancy.
Methods
Study subjects were selected from participants of a case–
control study designed to investigate risk factors of pla-
cental abruption. Study population and data collection 
procedures, described before, were briefly as follows [13]. 
Participants were women who delivered at the Hospital 
Nacional dos de Mayo, Instituto Especializado Materno 
Perinatal, Hospital Edgardo Rebagliati Martins, Hospi-
tal Nacional Hipolito Unanue, and Hospital Nacional 
Docente Madre Niño San Bartolomè in Lima, Peru, dur-
ing the period from September 2006 through Septem-
ber 2008. This study was approved by the Institutional 
Review Board of the University of Washington. All study 
participants provided written informed consent.
All participating hospitals are tertiary care reference 
hospitals that manage high-risk pregnancies in Lima, 
Peru; and experienced maternal-fetal-medicine spe-
cialists cared for all patients. The diagnosis of placental 
abruption was based on clinical examination performed 
by the attending physician. For the research diagnosis 
of placental abruption, we required evidence of blood 
clot behind the placenta accompanied by at least two of 
the following signs and symptoms: (1) vaginal bleeding 
in late pregnancy that was not associated with placenta 
previa or cervical lesions; (2) uterine tenderness and/or 
abdominal pain; and (3) fetal distress or death. Controls 
were selected from eligible women who delivered at the 
participating institutions during the study period. Eligi-
ble controls were women who did not have a diagnosis 
of placental abruption and whose medical record review 
later confirmed this fact. For this present pilot and fea-
sibility study, we randomly selected 103 consecutive pla-
cental abruption cases from a total sample of 383 cases. 
Additionally, we sampled 102 non-abruption controls 
from a total of 369 controls.
Study subjects were recruited during their labor and 
delivery hospital stay. We used a standardized, structured 
questionnaire to collect information regarding maternal 
sociodemographic, medical, reproductive, and lifestyle 
characteristics during in-person interviews. All inter-
views were conducted by trained research interviewers. 
Information collected during the interviews included 
maternal age, marital status, employment status during 
pregnancy, medical history, pre-pregnancy weight, and 
smoking and alcohol consumption during pregnancy. 
Maternal and infant records were reviewed to collect 
detailed information concerning antepartum, labor, and 
delivery characteristics, as well as conditions of the new-
born. Maternal anthropometric measures (e.g., height 
and weight) were taken at the time of the interview. Ges-
tational age was based on the date of the last menstrual 
period and was confirmed by an ultrasound examination 
performed before 20  weeks gestation. Pre-pregnancy 
body mass index (BMI), a measure of overall maternal 
adiposity, was calculated as weight in kilograms divided 
by height in meters squared. Women were classified as 
lean (BMI <18.5  kg/m2), normal (BMI  =  18.5–24.9  kg/
m2), overweight (BMI  =  25.0–29.9  kg/m2) and obese 
(BMI ≥30.0 kg/m2).
Placentas were collected immediately after delivery. 
Placentas were weighed, double bagged and transported 
in coolers. The chorionic plate and overlying membranes 
were removed, and tissue biopsies (approximately 0.5 cm3 
each) were randomly obtained from 8 sites (4 maternal 
and 4 fetal). Care was taken to avoid the chorioamniotic 
membrane contamination. For this present study, biopsy 
samples taken from the fetal side, which consisted of 
trophoblast tissues, intervillous tissues, and chorionic 
villi, were sampled for genomic DNA extraction. Biopsies 
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were placed in cryotubes, snap frozen in liquid nitrogen, 
and stored at −80 °C until analysis.
A pooled sample (~20  g) from 4 fetal placental sam-
plings, representing the intervillous tissues, and cho-
rionic villi, was homogenized using a Tissue Tearor 
(Biospec Products Inc., Bartlesville, OK, USA) in a lysis 
buffer from the Qiamp DNA Mini Kit (Qiagen Inc, 
Valencia, CA, USA) with added Proteinase Kt. DNA 
was extracted using a standardized protocol adapted 
from Qiamp DNA Mini Kit (Qiagen Inc., Valencia, CA, 
USA). DNA, from aliquots of placental biopsies, was 
extracted using standard salting-out procedures [20] in a 
core facility (Roswell Park Cancer Institute, Buffalo, NY, 
USA). For quantification of mtDNA copy number, real-
time DNA PCR analysis was performed with the Nova-
QUANT™ Human Mitochondrial to Nuclear DNA Ratio 
Kit (catalog #72620 EMD Millipore, Billerica, MA, USA) 
according to the manufacturer’s instructions [21]. This kit 
provides plates pre-aliquoted with the primers to com-
pare the levels of two nuclear genes (BECN1 and NEB) 
to two mitochondrial genes (ND1 and ND6) in a real-
time quantitative polymerase chain reaction. Mitochon-
drial ND1 [GenBank KP875569 (3314–3467)] and ND6 
[GenBank: KP875569 (14341–14436)] encode NADH 
dehydrogenase 1 or NADH dehydrogenase 6 which are 
core subunit of the mitochondrial membrane respiratory 
chain NADH dehydrogenase (Complex I) that is believed 
to belong to the minimal assembly required for cataly-
sis. Complex I functions in the transfer of electrons from 
NADH to the respiratory chain in mitochondria. BECN1 
encodes beclin 1, autophagy related and locates in chro-
mosome 17q21 with 13 exons [GenBank: AC016889.28 
(89304–80432)]. NEB encodes nebullin, a giant pro-
tein component of the cytoskeletal matrix that coexists 
with the thick and thin filaments within the sarcom-
eres of skeletal muscle. NEB is located in chromosome 
2q22 with 183 exons [GenBank: NG_009382.2 (16079–
16195)]. 2 ng of DNA was added to 80 μL of SYBR Select 
Master Mix (catalog #4472908 Life Technologies, Carls-
bad, CA, USA) then 20 GenBank KP875569 (3314–3467L 
applied to each of the four wells of pre-aliquoted primers. 
Plates were run in the ABI Prism 7000 sequence detec-
tion system (Applied Biosystems, Foster City, CA, USA) 
with the cycling conditions: 95  °C for 10  min followed 
by 40 Cycles of: 95  °C for 15  s 64  °C for 1  min. Analy-
sis was done using the ABI Prism 7000 SDS software 
RQ Study Application version 1.1. Relative copy number 
method was used to calculate the mtDNA copy number. 
This method results in the highest sample throughput. 
Ct values, where Ct is defined as the cycle number in 
which fluorescence first crosses the threshold, obtained 
for each of the two target genes and two reference genes 
are used once to determine mtDNA copy numbers. This 
is accomplished by averaging the copy numbers calcu-
lated from the ND1/BECN1 pair and the ND6/NEB pair. 
To calculate copy number, calculation N = 2−ΔCt where 
ΔCt1  =  CtND1  −  CtBECN1 and ΔCt2  =  CtND6  −  CtNEB, 
then do the average of 2−ΔCt1 and 2−ΔCt2. All assays were 
performed without knowledge of pregnancy outcome.
We examined frequency distributions of maternal 
socio-demographic, medical characteristics, and medi-
cal and reproductive histories according to placental 
abruption case–control status. Continuous data were 
checked for normality and are presented as arithmetic 
mean ± standard deviation (SD) when normally distrib-
uted or median with interquartile range (IQR) when data 
were not normally distributed. Since the distribution of 
placental mtDNA copy number was skewed for cases and 
controls, differences in median values of mtDNA copy 
number between placental abruption cases and control 
groups were compared based on the Mann–Whitney U 
test. Categorical data are presented as frequencies (per-
cent) and numbers. To estimate the relative association of 
placental abruption with placental mtDNA copy number, 
we categorized each subject according to quartiles deter-
mined by the distribution of mtDNA relative copy num-
ber among controls. We used the lowest quartile as the 
referent group, and we estimated odds ratios (OR) and 
95 % confidence intervals (95 % CI) for each of the upper 
three quartiles. We then contrasted the highest two quar-
tile with the lowest two quartiles combined since we 
observed no evidence of association of placental abrup-
tion with mtDNA across the lower two quartiles (below 
the median). We also evaluated linear trends in risk by 
considering the four quartiles as a continuous variable 
after assigning a score to each quartile [22]. To assess 
confounding, covariates were entered into a logistic 
regression model one at a time. We then compared the 
adjusted and unadjusted odds ratios [22]. Final logistic 
regression models included covariates that altered unad-
justed odds ratios by at least 10 %, as well as those covari-
ates of a priori interest (e.g., maternal pre-pregnancy 
BMI). We considered the following covariates as possible 
confounders in this analysis: maternal age, parity, smok-
ing during pregnancy, no prenatal care, and gestational 
age at delivery. All analyses were performed using STATA 
9.0 statistical software.
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